LIFEのチャート
LIFEの企業情報
symbol | LIFE |
---|---|
会社名 | aTyr Pharma Inc (アティ―ル・ファ―マ) |
分野(sector) | Health Care ヘルスケア |
産業(industry) | Biotechnology: Biological Products (No Diagnostic Substances) |
業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連(Health Care) |
概要 | 事業概要 エータイヤ・ファーマ(aTyr Pharma Inc.)は臨床段階バイオ治療薬会社である。同社は、生理的調節因子のセットを利用して重度・希少疾患患者ため医薬品の発見・臨床開発に従事する。同社は恒常性を促進する天然に存在する蛋白質クラスの約300のフィジオクリンを発見した。同社のフィジオクリンは、肺、消化管、皮膚、脳や肝臓の重度疾患を含む組織機能不全を特徴とする様々な疾患に治療適用である。同社は、免疫成分による希少筋疾患(RMICs)治療用静脈内蛋白質治療薬である「Resolaris」の開発に従事する。また、ヒトヒスチジンアミノアシル転移リボ核酸(tRNA)合成酵素の様々なフィジオクリン領域から生じる活動に関連したヒト骨格筋組織中の細胞外経路である、骨格筋組織中の「Resokine」経路の発見に基づく「Resolaris」を開発した。 アティ―ル・ファ―マは米国の製薬会社。自己免疫疾患などの難病に対する医薬品の臨床開発に従事する。同社は損傷を受けた細胞をより健康な細胞に修復する天然のタンパク質を利用する治療薬を開発する。新薬「Resolaris」は成人における顔面肩甲上腕部筋ジストロフィ―の治療のため開発され、第一相臨床試験を完了した。 aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases. |
本社所在地 | 3545 John Hopkins Court Suite #250 San Diego CA 92121 USA |
代表者氏名 | John K. Clarke ジョン・K・クラーク |
代表者役職名 | Independent Chairman of the Board |
電話番号 | +1 858-731-8389 |
設立年月日 | 38596 |
市場名 | NASDAQ National Market System |
ipoyear | 2015年 |
従業員数 | 65人 |
url | www.atyrpharma.com |
nasdaq_url | https://www.nasdaq.com/symbol/life |
adr_tso | ― |
EBITDA | EBITDA(百万ドル) -41.51800 |
終値(lastsale) | 0.7798 |
時価総額(marketcap) | 23282458.1878 |
時価総額 | 時価総額(百万ドル) 21.19844 |
売上高 | 売上高(百万ドル) 0.00000 |
企業価値(EV) | 企業価値(EV)(百万ドル) -23.56356 |
当期純利益 | 当期純利益(百万ドル) -43.74300 |
決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 aTyr Pharma Inc revenues was not reported. Net loss decreased 17% to $21.1M. Lower net loss reflects Research and development decrease of 30% to $11.8M (expense) Stock-based Compensation in SGA decrease of 20% to $1.3M (expense) Stock-based Compensation in R&D decrease of 1% to $860K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.07 to -$0.71. |
LIFEのテクニカル分析
LIFEのニュース
The last Hawaiian princess, with a trust valued at $215 million, has died at the age of 96 2022/12/12 19:54:15 Kwhen Finance
aTyr Pharma, Inc. (LIFE) Q3 2022 Earnings Call Transcript 2022/11/11 01:32:07 Seeking Alpha
aTyr Pharma, Inc. (NASDAQ:NASDAQ:LIFE) Q3 2022 Earnings Conference Call November 10, 2022 05:00 PM ET Company Participants Ashlee Dunston - Director, IR & Corporate Communications…
aTyr Pharma GAAP EPS of -$0.46 in-line 2022/11/10 21:02:14 Seeking Alpha
aTyr Pharma press release (LIFE): Q3 GAAP EPS of -$0.46 in-line.Cash, restricted cash, cash equivalents and investments as of September 30, 2022, were $79.6 million
aTyr Pharma Announces Third Quarter 2022 Results and Provides Corporate Update 2022/11/10 21:00:00 Investors Atyrpharma
First patient dosed in Phase 3 EFZO-FIT™ study in patients with pulmonary sarcoidosis; multiple centers in the U.S. are open for enrollment. Company to prioritize resources towards largest value driver efzofitimod program. Ended the third quarter 2022 with $79.6 million in cash, restricted cash,
aTyr Pharma up 5% after hours following Orphan Drug Status for efzofitimod 2022/04/12 22:23:50 Seeking Alpha
The U.S. FDA has granted Orphan Drug Status to aTyr Pharma''s (LIFE) efzofitimod for systemic sclerosis.
aTyr Pharma files for $200M mixed shelf offering 2022/03/15 21:56:48 Seeking Alpha
aTyr Pharma (LIFE) has filed for a $200M mixed shelf offering.The filing does not necessarily indicate that a sale has begun, or will occur in the future.The company said it will use…
aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q4 2021 Results - Earnings Call Transcript 2022/03/15 03:02:02 Seeking Alpha
Avetta Launches Supply Chain Sustainability and ESG Risk Mitigation Solution on Avetta One Platform 2022/03/13 22:31:00 Kwhen Finance
aTyr Pharma up 5% after hours following Orphan Drug Status for efzofitimod 2022/04/12 22:23:50 Seeking Alpha
The U.S. FDA has granted Orphan Drug Status to aTyr Pharma''s (LIFE) efzofitimod for systemic sclerosis.
aTyr Pharma files for $200M mixed shelf offering 2022/03/15 21:56:48 Seeking Alpha
aTyr Pharma (LIFE) has filed for a $200M mixed shelf offering.The filing does not necessarily indicate that a sale has begun, or will occur in the future.The company said it will use…